Drospirenone for Oral Contraception and Hormone Replacement Therapy
@article{Motivala2012DrospirenoneFO, title={Drospirenone for Oral Contraception and Hormone Replacement Therapy}, author={Apurva A. Motivala and Bertram Pitt}, journal={Drugs}, year={2012}, volume={67}, pages={647-655} }
The use of combined estrogen/progesterone has been shown to result in an increased cardiovascular risk in randomised double-blinded trials. However, these studies used oral progestogen (progestin) preparations, which lack anti-mineralocorticoid activity and have suboptimal anti-androgenic activity compared with progesterone. Drospirenone is a unique progestogen that has clinically been shown to have anti-mineralocorticoid/anti-androgenic effects. Drospirenone in combination with estrogen is…
9 Citations
Estetrol/Drospirenone: A Review in Oral Contraception
- MedicineDrugs
- 2022
Estetrol/drospirenone is an effective and generally well-tolerated COC, with a potentially reduced risk of thrombosis, and may offer a contraceptive option with a lower risk for blood clots.
Structure-activity relationship study of diphenylamine-based estrogen receptor (ER) antagonists.
- Chemistry, BiologyBioorganic & medicinal chemistry
- 2015
Estrogenic activity of B-fluorinated o-carborane-1,2-bisphenol synthesized via S(N)Ar reaction.
- Chemistry, BiologyBioorganic & medicinal chemistry letters
- 2012
Design and Synthesis of Novel Breast Cancer Therapeutic Drug Candidates Based upon the Hydrophobic Feedback Approach of Antiestrogens
- Chemistry, BiologyMolecules
- 2019
Based upon hydrophobic feedback approaches, novel sulfur-containing ERα modulators (4 and 5) as breast cancer therapeutic drug candidates and docking simulation studies of compound 5d with the ERα BD revealed that the largeHydrophobic moiety of compounds 5d fit well into the hydrophilic pocket of the ER α LBD and that the sulfur atom of compound5d formed a sulfur–π interaction with the amino acid residue His524 of theERα LBD.
Cerebral angiography as a tool for diagnosis and management of idiopathic intracranial hypertension syndrome.
- MedicineClinical imaging
- 2022
References
SHOWING 1-10 OF 94 REFERENCES
Advances in oral hormonal contraception.
- Biology, MedicineZentralblatt fur Gynakologie
- 1995
Researchers continue to search for newer oral contraceptive formulations that retain the pill's beneficial effects while minimizing side effects, and the identification of selective gonane progestins that do not have the same atherogenetic impact as their predecessors.
Additive effect of drospirenone/17-beta-estradiol in hypertensive postmenopausal women receiving enalapril.
- MedicineAmerican journal of hypertension
- 2002
Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal models.
- Biology, MedicineContraception
- 1995
Effects of a New Hormone Therapy, Drospirenone and 17-&bgr;-Estradiol, in Postmenopausal Women With Hypertension
- MedicineHypertension
- 2006
Data show that DRSP combined with E2 significantly reduces BP in postmenopausal women with hypertension and did not induce significant increases in serum potassium, which may lead to a new benefit for this novel hormone therapy in postwomen's hypertension.
Antihypertensive Effects of Drospirenone With 17&bgr;-Estradiol, a Novel Hormone Treatment in Postmenopausal Women With Stage 1 Hypertension
- MedicineCirculation
- 2005
Combination therapy with DRSP/E2 significantly lowered both clinic and 24-hour systolic BP in postmenopausal women with stage 1 systolics hypertension, which may lead to benefit for cardiovascular risk reduction in this population of women.
Drospirenone: a Novel Progestogen with Antimineralocorticoid and Antiandrogenic Activity
- Biology, MedicineAnnals of the New York Academy of Sciences
- 1995
Drospirenone exerts potent progestogenic and antigonadotropic activity which was studied in various animal species and efficiently promotes the maintenance of pregnancy in ovariectomized rats, inhibits ovulation in rats and mice and stimulates endometrial transformation in the rabbit.
Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women.
- MedicineAmerican journal of hypertension
- 2005
The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential.
- Biology, MedicineContraception
- 1996
Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.
- Medicine, BiologyThe Journal of clinical endocrinology and metabolism
- 1995
To the authors' knowledge, this is the first report on a combined OC that leads to a small decrease in body weight and blood pressure and may be especially beneficial for women susceptible for a gain in weight and a rise in blood pressure.